Navigation Links
AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
Date:12/3/2008

All amounts are in U.S. dollars

QUEBEC CITY, Dec. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, announces that it has completed the transaction under the previously announced purchase and sale agreement with Cowen Healthcare Royalty Partners, L.P. ("CHRP") relating to AEterna Zentaris' rights to royalties on future sales of Cetrotide(R) covered by its license agreement with Merck Serono. AEterna Zentaris received $52.5 million from CHRP at closing, less certain transaction costs. Under the terms of the agreement with CHRP, AEterna Zentaris would receive an additional payment of $2.5 million from CHRP contingent on 2010 net sales of Cetrotide(R) reaching a specified level.

About Cetrotide(R) (cetrorelix)

Cetrotide(R) (cetrorelix) was the first luteinizing hormone-releasing hormone (LHRH) antagonist treatment approved for in vitro fertilization. It is administered to women to prevent premature ovulation in order to increase fertility success rate. Developed in cooperation with Medicine Nobel-Prize winner, Professor Andrew Schally of Veterans Affairs, Miami, Florida, it was launched in Europe in 1999 and in the United States in 2001. Cetrotide(R) is currently marketed worldwide by Merck Serono, except for Japan where it is marketed by Nippon Kayaku and Shionogi.

Cetrorelix is also currently in a Phase 3 program in benign prostatic hyperplasia involving 1,500 patients in North America and Europe. First results are expected in Q3 2009 with an NDA filing to follow in 2010 and potential launch in 2011.

About Cowen Healthcare Royalty Partners

Cowen Healthcare Royalty Partners ("CHRP") is a global healthcare private equity firm with over $500 million in capita
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)..., SHANGHAI, Nov. 9 /PRNewswire-Asia/ -- The p...n their evolution. The companies are facing signi... skyrocketing R&D costs, calls for,lower price...s together with,the financial crisis have made the...pharmaceutical companies are being forced to globa...
(Date:11/9/2009)..., VIENNA, Va., Nov. 9 C...day that Dr. Kenneth S. Rosenthal, Professor of Im...versities College of Medicine and Pharmacy, report...sts at the Cleveland Clinic and CEL-SCI on CEL-SCI...ed at the 7th GTCbio Vaccine: "All Things Consider...
(Date:11/9/2009)... Product release is a resear...bjects, research facilities and research safety st.... , Cedar Knolls, NJ (PRW...ounced today that it has unveiled Pristima™ ... research facilities that track the use and care o...
(Date:11/8/2009)...ovember 6, 2009 As global temperatures and energy...gy will be key to a sustainable future. An attra...two studies published online in Genome Research ...enome structures of bioethanol-producing microorga...cal in developing new technologies needed to imple...
Breaking Biology Technology:Pharma and Biotech Leaders to Converge in Shanghai 2CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response 2CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response 3Xybion Unveils Pristima™ VM, an Integrated Enterprise Software Solution for Vivarium and Veterinary Care Management 2Genomes of biofuel yeasts reveal clues that could boost fuel ethanol production worldwide 2
...s Pharma, the,Danish biopharmaceutical company dev...at Keith McCullagh, President and Chief Executive,...pany and its goals for,2008 at the Biotechnology I...Conference in New York, today, Monday February 11t...ral European Time). The conference is,being held a...
...28, The Royal,Marsden Hospital (Sutton, Surrey, UK...lated Arc Therapy (VMAT)* treatment in the world u...e the treatment, the hospital,used its existing El...n,linear accelerator control system., (Logo: htt...GO ), VMAT takes Intensity Modulated Radiation T...
...0 Doses of the CDC,s National Strategic...OLIS, Feb. 11 Sentry Logistic Solutions,announced...ention (CDC),signed a contract to outsource storag...ve of the influenza virus vaccine. Sentry will war...ses from its pharmaceutical cold,chain logistics c...
Other Biology Technology:Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008 2Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital 2The Centers for Disease Control & Prevention Signs Vaccine Storage and Distribution Contract with Sentry Logistic Solutions 2The Centers for Disease Control & Prevention Signs Vaccine Storage and Distribution Contract with Sentry Logistic Solutions 3
(Date:11/5/2009)...hers (NABT) will recognize Leonard C. Yannielli, p...y Community College (NVCC) in Waterbury, Connectic... the NABT annual professional development conferen...ado. , The Evolution Education Award is cosponso...es,(AIBS) and Biological Sciences Curriculum Stud...
(Date:11/4/2009)...luctant to officially endorse green tea as a cance...out its protective effects, including results of a...h , a journal of the American Association for Canc... cancer. , Vassiliki Papadimitrakopoulo, M.D., ...c/Head and Neck Medical Oncology at the University...
(Date:11/4/2009)...od obesity in the United States is reaching epidem...tising on daytime and prime time television devote...about the role television plays in obesity, a stud...f Nutrition Education and Behavior examines how f... contributor to the problem. , Researchers at th...
Breaking Biology News(10 mins):Biologists, educators recognize excellence in evolution education 2Does green tea prevent cancer? Evidence continues to brew, but questions remain 2TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium 13511 1Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium 13511 2Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium 13511 3VIVUS Reports Second Quarter 2009 Financial Results 54258 1VIVUS Reports Second Quarter 2009 Financial Results 54258 2VIVUS Reports Second Quarter 2009 Financial Results 54258 3VIVUS Reports Second Quarter 2009 Financial Results 54258 4VIVUS Reports Second Quarter 2009 Financial Results 54258 5VIVUS Reports Second Quarter 2009 Financial Results 54258 6VIVUS Reports Second Quarter 2009 Financial Results 54258 7Ohio Judge Rules Tobacco Settlement Funds Should Be Used as Intended to Reduce Tobacco Use and Save Lives 54255 1Ohio Judge Rules Tobacco Settlement Funds Should Be Used as Intended to Reduce Tobacco Use and Save Lives 54255 2
...r gene has been discovered by scientists at the Lu...tic Surgery Clinic at the Sahlgrenska Academy in S...tain hereditary deformity syndrome run a nearly tw...r than expected. , Several research teams around ...ary breast cancer genes, but thus far few have bee...
...ng Project, funded by the National Institute of Al...National Institutes of Health (NIH), announced tod...ire genetic blueprints of more than 2,000 human an...d the world have been completed and the sequence d...information will help scientists understand how in...
...of York have won a grant of £110,000 to investigat...sease. , Dr Jason Lynam and Dr Ian Fairlamb, of t... awarded the funding by the Leverhulme Trust for a...for the controlled release of carbon monoxide into...inflammatory, and they want to explore its potenti...
Other Biology News:New hereditary breast cancer gene discovered 22,000 influenza virus genomes now completed and publicly accessible 2Research to spotlight carbon monoxide benefits 2
CCF4-AM from Invitrogen
IPTG Solution from Bioline
Non-Rad Detection Kit from BD Biosciences Pharmingen
Chicken Anti-Human ADI1 Polyclonal Antibody, Unconjugated from Abcam
Biology Products: